Sanofi's rivals in the insulin field are nipping at its heels – Lantus sales dipped 5 per cent in the first half of 2015, and analysts don't expect Toujeo to make up for its decline.

In Q3, sales of Lantus were down 9.8% compared with the same period last year, at just under $1.4 billion. Sanofi announced this week plans to cut 20% of jobs in its US diabetes and cardiovascular ...

MONROE COUNTY, Pa. - Sanofi, maker of anti-inflammation drug Dupixent, will report third-quarter earnings Friday before the opening of U.S. markets. Paris-based Sanofi is the parent company of ...

US pharma major Eli Lilly today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase III clinical trials ...